| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.61(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,969 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
110,593 |
276,438 |
434,458 |
898,780 |
| Total Sell Value |
$6,689,254 |
$18,972,868 |
$24,231,754 |
$44,996,315 |
| Total People Sold |
7 |
8 |
8 |
12 |
| Total Sell Transactions |
9 |
21 |
39 |
85 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Blum Robert I |
President & CEO |
• • – |
2019-10-15 |
4 |
AS |
$11.16 |
$66,975 |
D/D |
(6,000) |
238,022 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-10-03 |
4 |
AS |
$11.22 |
$16,830 |
D/D |
(1,500) |
122,067 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2019-09-16 |
4 |
AS |
$12.74 |
$76,469 |
D/D |
(6,000) |
244,022 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-09-05 |
4 |
AS |
$13.69 |
$20,531 |
D/D |
(1,500) |
123,567 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2019-08-15 |
4 |
AS |
$12.64 |
$75,815 |
D/D |
(6,000) |
250,022 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-08-08 |
4 |
AS |
$13.52 |
$20,280 |
D/D |
(1,500) |
125,067 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2019-07-15 |
4 |
AS |
$10.94 |
$65,632 |
D/D |
(6,000) |
256,022 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-07-11 |
4 |
S |
$11.26 |
$16,890 |
D/D |
(1,500) |
126,567 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2019-06-17 |
4 |
AS |
$9.71 |
$58,238 |
D/D |
(6,000) |
262,022 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-06-06 |
4 |
AS |
$10.31 |
$15,463 |
D/D |
(1,500) |
128,067 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-05-02 |
4 |
AS |
$8.29 |
$12,430 |
D/D |
(1,500) |
129,567 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-04-04 |
4 |
AS |
$8.31 |
$12,465 |
D/D |
(1,500) |
131,067 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-03-07 |
4 |
AS |
$5.98 |
$8,970 |
D/D |
(1,500) |
132,567 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
134,067 |
|
- |
|
| Cragg David |
SVP Human Resources |
• – – |
2019-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
116,783 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2019-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
268,022 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2019-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
50,000 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-02-07 |
4 |
AS |
$7.28 |
$10,920 |
D/D |
(1,500) |
84,067 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2019-01-10 |
4 |
AS |
$7.31 |
$10,965 |
D/D |
(1,500) |
85,567 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2019-01-04 |
4 |
AS |
$7.11 |
$28,432 |
D/D |
(4,000) |
148,022 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2018-12-06 |
4 |
AS |
$7.38 |
$11,070 |
D/D |
(1,500) |
87,067 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2018-12-06 |
4 |
AS |
$7.50 |
$29,988 |
D/D |
(4,000) |
152,022 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2018-11-05 |
4 |
AS |
$7.11 |
$28,446 |
D/D |
(4,000) |
156,022 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2018-11-01 |
4 |
AS |
$6.68 |
$10,020 |
D/D |
(1,500) |
88,567 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2018-10-05 |
4 |
AS |
$8.79 |
$35,178 |
D/D |
(4,000) |
160,022 |
|
- |
|
710 Records found
|
|
Page 25 of 29 |
|
|
1.22 (2.31%) 
